Sacral Neuromodulation in Parkinson’s Disease: An Effective Avenue of Treatment

Martin S1, Zillioux J1, Kocher N1, Vasavada S1, Rackley R1, Goldman H1

1. Cleveland Clinic

KEYWORDS: Neuromodulation, Neuropathies: Central, Overactive Bladder, Urgency Urinary Incontinence

Parkinson’s disease (PD) is the second-most common degenerative neurologic disease worldwide. Overactive bladder (OAB) is prevalent in this population, with lower urinary tract symptoms (LUTS) present in 27-85% of PD patients. [1] OAB/LUTS can be challenging to treat due to risks associated with polypharmacy (anticholinergics) and difficulty with self-catheterization in cases of retention (Onabotulinumtoxin-A). Sacral neuromodulation (SNM) is an attractive treatment option, especially with the recent introduction of MRI conditional technology, but remains understudied in PD. The largest study of SNM in PD was a retrospective chart review of 15 patients, which found that 60% of patients progressed to permanent implant. [2] We have utilized SNM in PD patients for some time, therefore, the aim of our study was to assess the safety, efficacy and long-term outcomes of SNM in the PD population.

свернуть